Title
Digital Peripheral Arterial Tonometry and Cardiovascular Disease Events: The Framingham Heart Study
Date Issued
01 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Cooper L.L.
Wang N.
Beiser A.S.
Romero J.R.
Aparicio H.J.
Lioutas V.A.
Benjamin E.J.
Larson M.G.
Vasan R.S.
Mitchell G.F.
Seshadri S.
Hamburg N.M.
Publisher(s)
Wolters Kluwer Health
Abstract
Background and Purpose: Novel noninvasive measures of vascular function are emerging as subclinical markers for cardiovascular disease (CVD) and may be useful to predict CVD events. The purpose of our prospective study was to assess associations between digital peripheral arterial tonometry (PAT) measures and first-onset major CVD events in a sample of FHS (Framingham Heart Study) participants. Methods: Using a fingertip PAT device, we assessed pulse amplitude in Framingham Offspring and Third Generation participants (n=3865; mean age, 55±14 years; 52% women) at baseline and in 30-second intervals for 4 minutes during reactive hyperemia. The PAT ratio (relative hyperemia index) was calculated as the post-to-pre occlusion pulse signal ratio in the occluded arm, relative to the same ratio in the control (nonoccluded) arm, and corrected for baseline vascular tone. Baseline pulse amplitude and PAT ratio during hyperemia are measures of pressure pulsatility and microvascular function in the finger, respectively. We used Cox proportional hazards regression to relate PAT measures in the fingertip to incident CVD events. Results: During follow-up (median, 9.2 years; range, 0.04-10.0 years), 270 participants (7%) experienced new-onset CVD events (n=270). In multivariable models adjusted for cardiovascular risk factors, baseline pulse amplitude (hazard ratio [HR] per 1 SD, 1.04 [95% CI, 0.90-1.21]; P=0.57) and PAT ratio (HR, 0.95 [95% CI, 0.84-1.08]; P=0.43) were not significantly related to incident composite CVD events, including myocardial infarction or heart failure. However, higher PAT ratio (HR, 0.76 [95% CI, 0.61-0.94]; P=0.013), but not baseline pulse amplitude (HR, 1.15 [95% CI, 0.89-1.49]; P=0.29), was related to lower risk for incident stroke. In a sensitivity analysis by stroke subtype, higher PAT ratio was related to lower risk of incident ischemic stroke events (HR, 0.68 [95% CI, 0.53-0.86]; P=0.001). Conclusions: Novel digital PAT measures may represent a marker of stroke risk in the community.
Start page
2866
End page
2873
Language
English
OCDE Knowledge area
Epidemiología
Sistema cardiaco, Sistema cardiovascular
Subjects
Scopus EID
2-s2.0-85113786618
PubMed ID
Source
Stroke
ISSN of the container
00392499
Sponsor(s)
Dr Mitchell is the owner of Cardiovascular Engineering, Inc, a company that develops and manufactures devices to measure vascular stiffness; serves as a consultant to and receives honoraria from Novartis, Merck, Bayer, Servier, and Philips; and reports research grants from Novartis. Dr Benjamin received an unrestricted grant from Itamar Medical for this project. In 2008, Itamar Industries (http://www.itamar-medical.com)—the maker of the peripheral arterial tonometry (PAT) device—gave an unrestricted research grant to the Boston University. Dr Benjamin received no personal salary, honoraria, or consulting fees; the grant was to perform analyses of the epidemiology, genetics, and prognosis of PAT. The grant subscribed to the National Heart, Lung, and Blood Institute guidelines for third-party funding (http://www.nhlbi.nih.gov/funding/policies/thirdparty.htm; total cost, $100000). Itamar also donated the PAT devices to the Boston University FHS (Framingham Heart Study) from 1999 to 2006. The other authors report no conflicts.
2R01HL092577, 1R01HL141434 01A1, 2U54HL120163, 1R01AG066010, HHSN268201500001I, N01-HC 25195, 1R01HL60040, and 1RO1HL70100 from the National Institutes of Health; research grant 18SFRN34110082 from the American Heart Association; and by an unrestricted research grant from Itamar Medical for this project. Dr Cooper is partially funded by grant 2R25HL105400. Dr Hamburg is funded by U54HL120163, AHA 20SRFRN35120118, and R01 HL115391. Dr Seshadri is funded by grant NS017950 from the National Institute of Neurological Disorders and Stroke. Dr Vasan is supported, in part, by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Aparicio is funded by a research supplement AG054076-02S1 from the National Institute on Aging and by the Aram V. Chobanian Assistant Professorship from the Boston University School of Medicine.
This work was supported by the National Heart, Lung, and Blood Institute FHS (Framingham Heart Study; contract No. N01-HC-25195, HHS-N268201500001I, and 75N92019D00031) and by HL076784, AG028321, HL070100, HL060040, HL080124, HL071039, HL077447, HL107385, HL126136, HL128914, and 2-K24-HL04334. Dr Mitchell was funded by research grants HL094898, DK082447, HL107385, HL104184, and HL126136 from the National Institutes of Health. Dr Benjamin was funded by research grants
Sources of information:
Directorio de Producción Científica
Scopus